L2 Asset Management LLC Invests $492,000 in Encompass Health Corporation $EHC

L2 Asset Management LLC acquired a new stake in shares of Encompass Health Corporation (NYSE:EHC) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor acquired 4,867 shares of the company’s stock, valued at approximately $492,000.

Other hedge funds also recently made changes to their positions in the company. Persistent Asset Partners Ltd bought a new position in Encompass Health in the second quarter valued at $36,000. Keating Financial Advisory Services Inc. bought a new stake in Encompass Health during the second quarter worth about $39,000. Assetmark Inc. boosted its holdings in shares of Encompass Health by 89.6% in the 1st quarter. Assetmark Inc. now owns 455 shares of the company’s stock worth $44,000 after purchasing an additional 215 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Encompass Health by 36,200.0% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 363 shares of the company’s stock worth $46,000 after purchasing an additional 362 shares in the last quarter. Finally, Aster Capital Management DIFC Ltd bought a new position in shares of Encompass Health during the 4th quarter valued at about $55,000. 97.25% of the stock is owned by institutional investors.

Encompass Health Stock Down 0.6%

EHC opened at $120.18 on Wednesday. Encompass Health Corporation has a 12 month low of $92.77 and a 12 month high of $127.99. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.76. The business’s 50-day moving average price is $111.85 and its 200-day moving average price is $106.83. The company has a market cap of $11.86 billion, a P/E ratio of 19.57, a P/E/G ratio of 2.45 and a beta of 0.72.

Encompass Health (NYSE:EHC) last issued its earnings results on Wednesday, August 5th. The company reported $1.55 earnings per share for the quarter, beating the consensus estimate of $1.48 by $0.07. Encompass Health had a return on equity of 18.08% and a net margin of 10.01%.The company had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.57 billion. Encompass Health’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same period in the prior year, the business posted $1.40 EPS. Encompass Health has set its FY 2026 guidance at 6.020-6.250 EPS. On average, equities analysts expect that Encompass Health Corporation will post 6.09 EPS for the current year.

Encompass Health Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Thursday, October 1st will be issued a $0.21 dividend. This is a positive change from Encompass Health’s previous quarterly dividend of $0.19. This represents a $0.84 annualized dividend and a dividend yield of 0.7%. The ex-dividend date is Thursday, October 1st. Encompass Health’s dividend payout ratio (DPR) is 12.38%.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on EHC shares. TD Cowen raised their price objective on Encompass Health from $125.00 to $140.00 and gave the company a “buy” rating in a report on Monday, August 10th. Truist Financial increased their price target on shares of Encompass Health from $140.00 to $150.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Leerink Partners set a $152.00 price target on shares of Encompass Health in a research note on Friday, May 22nd. Barclays boosted their price objective on shares of Encompass Health from $140.00 to $144.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. Finally, Weiss Ratings raised shares of Encompass Health from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 12th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, Encompass Health has an average rating of “Buy” and a consensus price target of $148.71.

Insider Activity at Encompass Health

In related news, EVP John Patrick Darby sold 8,906 shares of Encompass Health stock in a transaction on Monday, August 10th. The shares were sold at an average price of $125.95, for a total value of $1,121,710.70. Following the transaction, the executive vice president directly owned 75,041 shares of the company’s stock, valued at $9,451,413.95. The trade was a 10.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Mark J. Tarr sold 173,148 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $125.47, for a total transaction of $21,724,879.56. Following the sale, the chief executive officer owned 267,814 shares of the company’s stock, valued at $33,602,622.58. This represents a 39.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 1.80% of the stock is currently owned by company insiders.

Encompass Health Profile

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.